Published: 18 May 2024
Author(s): Òscar Miró, Julio Núñez, Joan Carles Trullàs, Pedro Lopez-Ayala, Lluís Llauger, Aitor Alquézar-Arbé, Gema Miñana, Anna Mollar, Rafael de la Espriella, Miguel Lorenzo, Javier Jacob, Begoña Espinosa, Vanesa Garcés-Horna, Alfons Aguirre, María José Fortuny, Gemma Martínez-Nadal, Víctor Gil, Christian Mueller, Pere Llorens, ICA-SEMES, INCLIVA, ALCALOTIC research groups
Section: Original Article

Heart failure (HF) is a highly prevalent cardiovascular condition in people over 65 years old [1]. Mortality associated with HF decompensations (acute HF; AHF) is high, with 30-day and 1-year all-cause mortality surpassing 10 % and 30 %, respectively [2-4]. In addition, an increased risk of adverse events occurs during the vulnerable phase, i.e., the weeks after patient discharge from the hospital due to an AHF episode [5,6]. Some of these adverse events have been related to remaining congestion at discharge as well as decreased effectiveness of loop diuretics once patients are discharged home.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness